Search | IOVS | ARVO Journals

Showing 1 – 20 of 73

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Integrin peptide inhibitor for the treatment of intermediate Age Related Macular Degeneration

Hugo Quiroz-Mercado; Jose Luis Guerrero-Naranjo; Roberto Gonzalez-Salinas; Luis F Hernandez-Zimbron; Ruben Zamora; Rosario Gulías-Cañizo; Lenin Ochoa-De la Paz; Lisa Karageozian; Vicken Karageozian; Linda Kutscher; John Y Park; Hampar Karageozian

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1943.

ARVO Annual Meeting Abstract September 2016

Antibiotics resistance in culture-positive endophthalmitis

Raul Velez-Montoya; Vidal Soberon; carlos Sjoholm; Juan M. Elizondo-Camacho; Guillermo Salcedo; Jose Luis Guerrero-Naranjo; Jans J Fromow-Guerra; Gerardo Garcia-Aguirre; Virgilio Morales-Canton

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6375.

ARVO Annual Meeting Abstract June 2015

Interim Results of a Dose Escalation Study of NT-503 Encapsulated Cell Therapy for the Treatment of Choroidal Neovascularization in AMD

Anat Loewenstein; Hugo Quiroz-Mercado; Jose Luis Guerrero-Naranjo; Sergio Rojas; Arturo Santos; Juan Carlos Altamirano; Yael Morales; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2277.

ARVO Annual Meeting Abstract June 2013

Safety of intravitreal quinupristin / dalfopristin in an animal model

Veronica Giordano; Sergio Hernandez-Da Mota; Jose Luis Guerrero-Naranjo; Tania Adabache Guel; Samantha Salinas Longoria; Sonia Corredor-Casas; Guillermo Salcedo-Villanueva; Juan Manuel Jimenez-Sierra; Virgilio Morales-Canton

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1966.

ARVO Annual Meeting Abstract June 2013

Safety of implantation of the NT-503 device in patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration

Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado; Gustavo Sanchez-Bermudez; Fernando Schoonewolff; Samantha Salinas Longoria; Rafael Romero Vera; Weng Tao; Richard Beckman; Virgilio Morales-Canton; Asociacion para Evitar la Ceguera en Mexico I.A.P.

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3298.

ARVO Annual Meeting Abstract June 2013

Integrin Peptide Therapy: The First Wet AMD Experience

Peter Kaiser; David Boyer; Peter Campochiaro; Jose Luis Guerrero-Naranjo; Jeffrey Heier; Julia Kornfield; Baruch Kuppermann; Hugo Quiroz-Mercado; Samantha Salinas Longoria; Shulamit Schwartz

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2177.

ARVO Annual Meeting Abstract March 2012

Intravitreal Injection of Integrin Peptide ALG-1001 for the Induction of Posterior Vitreous Detachment in Rabbit Eyes

Hugo E. Sepulveda-Vazquez; Jose Luis Guerrero-Naranjo; Fernando Schoonewolff; Hugo Quiroz-Mercado; Hampar L. Karageozian; John Y. Park; Vicken Karageozian; Sonia Corredor; Abelardo Rodriguez-Reyes; Marc Kirshbaum

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5360.

ARVO Annual Meeting Abstract March 2012

Comparison of Short Term Outcomes After Intravitreal Bevacizumab Versus Ranibizumab in the Treatment of Stage 3 Retinopathy of Prematurity

Jose Luis Guerrero-Naranjo; Fernando Schoonewolff; Jans J. Fromow-Guerra; Virgilio Morales-Canton; Gerardo Garcia-Aguirre; Hugo Quiroz-Mercado; Maria A. Martinez-Castellanos

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5857.

ARVO Annual Meeting Abstract April 2011

Worldwide Experiences With Intravitreal Anti-VEGFs for ROP

Edgard Omar Rodriguez Torres, Sr.; Maria A. Martinez; Hugo Quiroz Mercado; Jose L. Guerrero Naranjo; Wu Wei Chi; Robison V. Paul Chan; Kuo His Kung; Alay S. Banker

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3125.

ARVO Annual Meeting Abstract April 2011

Five Years Follow up of Intravitreal Bevacizumab Therapy in the Treatment of Retinopathy of Prematurity. Anatomical, Functional, and Neurodevelopmental Analysis

Jose Luis Guerrero-Naranjo; Mariana Martinez-Castellanos; Virgilio Morales-Canton; Gerardo Garcia-Aguirre; Paul Chan; Hugo Quiroz-Mercado

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3146.

ARVO Annual Meeting Abstract April 2011

Four Years Follow-up of Intravitreal Bevacizumab Therapy in the Treatment of Retinopathy of Prematurity, India-Mexico Collaborative Group Experience

Axel Orozco-Hernandez; Alay Banker; Deepa Banker; Hugo Quiroz-Mercado; Rohan Chauhan; Robison V. Chan; Jose Luis Guerrero-Naranjo; Gerardo Garcia-Aguirre; Maria Ana Martinez-Castellanos

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3161.

ARVO Annual Meeting Abstract April 2011

Methods and Techniques for Intravitreal Antiangiogenic Therapy (IAT) in Retinopathy of Prematurity (ROP) : A 196 Cases Experience

Hugo Quiroz-Mercado; Jose Luis Guerrero-Naranjo; Gerardo Garcia-Aguirre; Benjamin J. Ernst; Cirag C. Patel; Paul R. Chan; Maria Ana Martinez-Castellano

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3169.

ARVO Annual Meeting Abstract April 2011

Evaluation of Retinal Toxicity by ERG Before and After Pars Plana Vitrectomy in ILM Peeling Assisted by Brilliant Blue G Staining at a Concentration of 1 mg/ml, 6 Months of Follow Up

Ana I. Ortiz; Miriam Jessica J. Lopez-Miranda; Valentina Franco-Cardenas; Jose Luis Guerrero-Naranjo; Juan Jimenez-Sierra; Hugo Quiroz-Mercado; Virgilio Morales-Canton

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6116.

ARVO Annual Meeting Abstract April 2011

Silicone Oil Removal Through a 23-Gauge Sclerotomy: Introduction of a Low-Cost Effective Technique

Virgilio Morales-Canton; Efrain Romo-Garcia; Jans J. Fromow-Guerra; Jose Luis Guerrero-Naranjo; Juan Manuel Jimenez-Sierra

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):531.

ARVO Annual Meeting Abstract April 2010

Topical Anesthesia in Antiangiogenic Therapy for Retinopathy of Prematurity

J. Guerrero-Naranjo; M. A. Martinez-Castellanos; R. V. Chan; V. Morales-Canton

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):2810.

ARVO Annual Meeting Abstract April 2010

Measurement of Pain During 23 Gauge Vitrectomy With Topical Anesthesia

J. Lesso-Zamora; J. Guerrero-Naranjo; J. De la Luz-Osnaya; A. Morales-Delgado; M. Martínez-Castellanos

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):2565.

ARVO Annual Meeting Abstract April 2010

Comparative Study Between Bevacizumab and 3-Epigallocatequin Gallate (EGCG) in the Regulation for VEGF and PEDF Expression in an Animal Model: Pilot Study

E. Romo-Garcia; J. Flores-Estrada; G. Salcedo-Villanueva; J. Guerrero-Naranjo; J. Jimenez-Sierra; H. Quiroz-Mercado; V. Morales-Canton

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4744.

ARVO Annual Meeting Abstract April 2010

Antiangiogenic Therapy In The Treatment For Retinopathy Of Prematurity, Four Years Follow Up. What We Have Learned.

M. A. Martinez-Castellanos; H. Quiroz-Mercado; J. Guerrero-Naranjo; G. Garcia-Aguirre; R. V. Chan

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5294.

ARVO Annual Meeting Abstract April 2010

Evaluation of Retinal Toxicity by ERG Before and After Pars Plana Vitrectomy in ILM Peeling Assisted by Brilliant Blue G Staining at a Concentration of 1 mg/ml. Pilot Study

V. Franco-Cardenas; M. J. Lopez-Miranda; E. Torres-Porras; H. Ruiz-Garcia; G. Garcia-Aguirre; J. L. Guerrero-Naranjo; J. M. Jimenez-Sierra; H. Quiroz-Mercado; V. Morales-Canton

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5586.

ARVO Annual Meeting Abstract April 2010

Vascular Changes After Intravitreal Injection of Ranibizumab in the Treatment of Stage Iii, Threshold and Pre-Threshold Retinopathy of Prematurity (rop)

L. Ruiz-Garcia; M. A. Martinez-Castellanos; G. Garcia-Aguirre; J. L. Guerrero-Naranjo; H. Quiroz-Mercado; P. Chan

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5920.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Integrin peptide inhibitor for the treatment of intermediate Age Related Macular Degeneration

Antibiotics resistance in culture-positive endophthalmitis

Interim Results of a Dose Escalation Study of NT-503 Encapsulated Cell Therapy for the Treatment of Choroidal Neovascularization in AMD

Safety of intravitreal quinupristin / dalfopristin in an animal model

Safety of implantation of the NT-503 device in patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration

Integrin Peptide Therapy: The First Wet AMD Experience

Intravitreal Injection of Integrin Peptide ALG-1001 for the Induction of Posterior Vitreous Detachment in Rabbit Eyes

Comparison of Short Term Outcomes After Intravitreal Bevacizumab Versus Ranibizumab in the Treatment of Stage 3 Retinopathy of Prematurity

Worldwide Experiences With Intravitreal Anti-VEGFs for ROP

Five Years Follow up of Intravitreal Bevacizumab Therapy in the Treatment of Retinopathy of Prematurity. Anatomical, Functional, and Neurodevelopmental Analysis

Four Years Follow-up of Intravitreal Bevacizumab Therapy in the Treatment of Retinopathy of Prematurity, India-Mexico Collaborative Group Experience

Methods and Techniques for Intravitreal Antiangiogenic Therapy (IAT) in Retinopathy of Prematurity (ROP) : A 196 Cases Experience

Evaluation of Retinal Toxicity by ERG Before and After Pars Plana Vitrectomy in ILM Peeling Assisted by Brilliant Blue G Staining at a Concentration of 1 mg/ml, 6 Months of Follow Up

Silicone Oil Removal Through a 23-Gauge Sclerotomy: Introduction of a Low-Cost Effective Technique

Topical Anesthesia in Antiangiogenic Therapy for Retinopathy of Prematurity

Measurement of Pain During 23 Gauge Vitrectomy With Topical Anesthesia

Comparative Study Between Bevacizumab and 3-Epigallocatequin Gallate (EGCG) in the Regulation for VEGF and PEDF Expression in an Animal Model: Pilot Study

Antiangiogenic Therapy In The Treatment For Retinopathy Of Prematurity, Four Years Follow Up. What We Have Learned.

Evaluation of Retinal Toxicity by ERG Before and After Pars Plana Vitrectomy in ILM Peeling Assisted by Brilliant Blue G Staining at a Concentration of 1 mg/ml. Pilot Study

Vascular Changes After Intravitreal Injection of Ranibizumab in the Treatment of Stage Iii, Threshold and Pre-Threshold Retinopathy of Prematurity (rop)

To View More...

You must be signed into an individual account to use this feature.